Pharmerit International, 4350 East-West Hwy, Suite 1110, Bethesda, MD 20814, USA.
Celldex Therapeutics, 53 I-78 Frontage Rd, Hampton, NJ 08827, USA.
Future Oncol. 2019 Mar;15(9):1007-1020. doi: 10.2217/fon-2018-0407. Epub 2019 Feb 5.
This analysis estimated the overall survival, treatment patterns and economic burden of elderly metastatic triple-negative breast cancer patients.
MATERIALS & METHODS: Patients (≥66 years) with metastatic triple-negative breast cancer were identified from the SEER-Medicare database. Treatment patterns were defined in terms of first, second and third or more regimens. Healthcare resource use and costs were reported over the follow-up period and over the treatment duration of each regimen.
A total of 51% of patients did not receive chemotherapy. Taxanes were most commonly used. Median survival was 7 months. The mean cumulative (per patient per month) cost per patient was US$73,586 (US$10,084). Mean cost in first and second regimen were US$26,950 and US$33,347.
About half of patients did not receive chemotherapy. Receipt of increasing regimens led to higher mean costs and healthcare resource use.
本分析评估了老年转移性三阴性乳腺癌患者的总生存期、治疗模式和经济负担。
从 SEER-Medicare 数据库中确定了患有转移性三阴性乳腺癌的患者（≥66 岁）。根据一线、二线和三线或更多线治疗方案来定义治疗模式。报告了随访期间和每个治疗方案期间的医疗资源使用和成本。
共有 51%的患者未接受化疗。紫杉烷类药物最常用。中位生存期为 7 个月。每位患者每月的累积（每位患者每月）成本为 73586 美元（10084 美元）。一线和二线方案的平均费用分别为 26950 美元和 33347 美元。
约一半的患者未接受化疗。接受更多的治疗方案会导致更高的平均成本和医疗资源使用。
